| __timestamp | Axsome Therapeutics, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 5699000000 |
| Thursday, January 1, 2015 | 2419289 | 5001000000 |
| Friday, January 1, 2016 | 6343648 | 5002000000 |
| Sunday, January 1, 2017 | 7206691 | 4849000000 |
| Monday, January 1, 2018 | 9351522 | 4551000000 |
| Tuesday, January 1, 2019 | 13598030 | 4871000000 |
| Wednesday, January 1, 2020 | 28896749 | 7661000000 |
| Friday, January 1, 2021 | 66646205 | 7690000000 |
| Saturday, January 1, 2022 | 159253661 | 7814000000 |
| Sunday, January 1, 2023 | 323123000 | 7772000000 |
| Monday, January 1, 2024 | 411359000 | 8414000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Bristol-Myers Squibb Company, a titan in the industry, has consistently maintained high SG&A expenses, peaking at approximately $7.8 billion in 2022. This reflects their expansive operations and robust market presence. In contrast, Axsome Therapeutics, Inc., a burgeoning player, has seen a dramatic rise in SG&A expenses, skyrocketing from a modest $1.4 million in 2014 to over $320 million in 2023. This 22,000% increase underscores their aggressive growth strategy and market penetration efforts. While Bristol-Myers Squibb's expenses have grown by about 36% over the same period, their scale allows for a more stable financial trajectory. This comparison highlights the dynamic strategies of established versus emerging pharmaceutical companies in managing operational costs.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?